查看購物車
  • Simplified Chinese
  • English
  • Japanese
  • Korean
歐洲基因組癌症面板和分析市場：分析和預測（2023-2033）
市場調查報告書
商品編碼
1408631

歐洲基因組癌症面板和分析市場：分析和預測（2023-2033）

Europe Genomic Cancer Panel and Profiling Market: Analysis and Forecast, 2023-2033
出版日期: | 出版商: BIS Research | 英文 92 Pages | 商品交期: 1-5個工作天內

價格

截至2023年，歐洲基因組癌症面板和分析市場規模為26.4億美元，預計2033年將達到65億美元。

2023-2033年預測期間的複合年成長率預計為9.42%。這種成長是由基因組研究的進步和對腫瘤學精準治療的日益重視所推動的。

主要市場統計數據
預測期 2023-2033
2023年評估 26.4億美元
2033年預測 65億美元
複合年成長率 9.42%

基因組癌症組合和分析是癌症檢測的現代方法，可在症狀出現之前檢查惡性的遺傳特徵。一個主要優點是這些面板可以提供廣泛的遺傳見解，促進早期檢測並促進客製化治療策略的發展。基因組癌症面板和分析市場正在擴大，因為這些技術具有改變癌症管理的變革潛力。這些面板允許醫療保健提供者識別特定的基因變化並相應地客製化干涉措施，從而提高我們對癌症遺傳學的理解。

在歐洲市場，基因癌症檢測和分析在癌症篩檢和管理方面越來越受歡迎。這些尖端技術提供了有關惡性的詳細遺傳資訊，從而可以進行早期檢測和個性化治療方法。這些面板的需求不斷增加，因為它們具有改變癌症管理的潛力。促進歐洲市場擴張的因素包括液體活體組織切片檢測的普及、生活方式改變導致的癌症風險增加以及早期檢測的需要。

該報告研究了歐洲基因組癌症面板和分析市場，並提供了市場概述，包括按應用、最終用戶、國家和進入市場的公司概況分類的趨勢。

目錄

執行摘要

第1章 市場

  • 市場範圍
  • 調查方法
  • 市場概況

第2章 產業分析

  • 法律要求
  • 專利分析

第3章市場動態

  • 概述
    • 影響分析
  • 市場促進因素
  • 市場抑制因素
  • 市場機會

第4章競爭考察

  • 概述
  • 關鍵策略和發展
  • 成長佔有率分析

第5章 按地區分類

  • 概述
  • 歐洲
    • 關鍵動態
    • 德國
    • 法國
    • 英國
    • 義大利
    • 西班牙
    • 其他地區

第6章 公司簡介

  • F. Hoffmann-La Roche Ltd
Product Code: BHP1775SS

“The Europe Genomic Cancer Panel and Profiling Market Expected to Reach $6.50 Billion by 2033.”

Introduction to Europe Genomic Cancer Panel and Profiling Market

As of 2023, the Europe genomic cancer panel and profiling market was valued at $2.64 billion and is expected to attain a value of $6.50 billion in 2033. The market is anticipated to grow at a CAGR of 9.42% during the forecast period 2023-2033. This growth is being driven by advances in genomic research and an increasing emphasis on precision therapy in oncology.

KEY MARKET STATISTICS
Forecast Period2023 - 2033
2023 Evaluation$2.64 Billion
2033 Forecast$6.50 Billion
CAGR9.42%

Market Introduction

Genomic cancer panels and profiling are a contemporary technique to cancer detection that examines the genetic characteristics of malignancies before symptoms occur. The capacity of these panels to provide extensive genetic insights facilitates early detection and the development of tailored treatment strategies, which is a considerable advantage. The genomic cancer panel and profiling market is expanding because to the transformational potential these technologies have for changing cancer management. These panels improve our understanding of cancer genetics by allowing healthcare providers to identify particular genetic changes and customize interventions accordingly.

In the European market, genetic cancer panels and profiling are gaining popularity for cancer screening and management. These modern technologies provide detailed genetic information about malignancies, allowing for early detection and individualized treatment regimens. The demand for these panels is increasing as a result of their transformational potential in changing cancer management. Factors driving market expansion in Europe include the growing popularity of liquid biopsy testing, increased cancer risk due to lifestyle changes, and the need for early detection.

Market Segmentation

Segmentation 1: by Application

  • Clinical
  • Research

Segmentation 2: by End User

  • Hospitals
  • Clinical and Diagnostic Laboratories
  • Research and Academic Institutes
  • Other End Users

Segmentation 3: by Country

  • U.K.
  • France
  • Italy
  • Germany
  • Spain

How can this report add value to an organization?

Product/Innovation Strategy: The Europe genomic cancer panel and profiling market has been extensively segmented based on various categories, such as application, end user, and country. This can help readers get a clear overview of the segments accounting for the largest share and the ones that are well-positioned to grow in the coming years.

Table of Contents

Executive Summary

1. Markets

  • 1.1. Market Scope
    • 1.1.1. Key Questions Answered in this Report
  • 1.2. Research Methodology
    • 1.2.1. Genomic Cancer Panel and Profiling Market: Research Methodology
    • 1.2.2. Data Sources
    • 1.2.3. Market Estimation Model
    • 1.2.4. Criteria for Company Profiling
  • 1.3. Market Overview
    • 1.3.1. Market Definition
    • 1.3.2. Market Footprint and Growth Potential
    • 1.3.3. Future Potential

2. Industry Analysis

  • 2.1. Legal Requirements
    • 2.1.1. Regulation of Genetic Tests
    • 2.1.2. NCCN Guidelines
    • 2.1.3. Reimbursement Scenario
  • 2.2. Patent Analysis
    • 2.2.1. Patent Filing Trend
    • 2.2.2. Patent Analysis (by Year)
    • 2.2.3. Patent Analysis (by Country)

3. Market Dynamics

  • 3.1. Overview
    • 3.1.1. Impact Analysis
  • 3.2. Market Drivers
    • 3.2.1. Rising Need for Cancer Profiling in Developed Countries Driving Demand for Genomic Panels and Profiling Tests
    • 3.2.2. Increase in Genomic Research Funding Expanding the Market for Genomic Cancer Panels and Profiling
    • 3.2.3. Technological Advancements in the Field of Informatics Expanding Consumer Reach
  • 3.3. Market Restraints
    • 3.3.1. Significant Implications of Reimbursement Reductions Impacting Growth of the Genomic Cancer Panel and Profiling Market
    • 3.3.2. Impact of High-Cost Pressure Hindering Development in Genomic Cancer Panel and Profiling Testing
  • 3.4. Market Opportunities
    • 3.4.1. Robust Pipeline of Genomic Cancer Panels and Profiling Tests Poised to Revolutionize Cancer Diagnosis
    • 3.4.2. Discovery of New Biomarkers Presents an Opportunity for the Development of Diagnostics Tools and Technologies

4. Competitive Insights

  • 4.1. Overview
  • 4.2. Key Strategies and Developments
    • 4.2.1. Product Launches, Approvals, and Upgradations
    • 4.2.2. Synergistic Activities
    • 4.2.3. Mergers and Acquisitions
    • 4.2.4. Business Expansions, Funding, and Licenses
  • 4.3. Growth-Share Analysis
    • 4.3.1. Growth-Share Analysis (by Technology), 2022

5. By Region

  • 5.1. Overview
  • 5.2. Europe
    • 5.2.1. Key Dynamics
    • 5.2.2. Germany
    • 5.2.3. France
    • 5.2.4. U.K.
    • 5.2.5. Italy
    • 5.2.6. Spain
    • 5.2.7. Rest-of-Europe

6. Company Profiles

  • 6.1. Overview
  • 6.2. F. Hoffmann-La Roche Ltd
    • 6.2.1. Company Overview
    • 6.2.2. Role of F. Hoffmann-La Roche Ltd in the Genomic Cancer Panel and Profiling Market
    • 6.2.3. Corporate Strategies
    • 6.2.4. Business Strategies
    • 6.2.5. Financials
    • 6.2.6. Analyst Perspective

List of Figures

  • Figure 1: Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 2: Genomic Cancer Panel and Profiling Market (by Application), % Share, 2022 and 2033
  • Figure 3: Genomic Cancer Panel and Profiling Market (by End User), % Share 2022 and 2033
  • Figure 4: Genomic Cancer Panel and Profiling Market Snapshot (by Region), $Billion, 2022
  • Figure 5: Genomic Cancer Panel and Profiling Market: Research Methodology
  • Figure 6: Primary Research Methodology
  • Figure 7: Bottom-Up Approach (Segment-Wise Analysis)
  • Figure 8: Top-Down Approach (Segment-Wise Analysis)
  • Figure 9: Genomic Cancer Panel and Profiling Workflow, End User Perspective
  • Figure 10: Genomic Cancer Panel and Profiling Workflow, Laboratory Technician Perspective
  • Figure 11: Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 12: General Testing Criterion According to the NCCN Guidelines
  • Figure 13: Reimbursement Components in the U.S.
  • Figure 14: Genomic Cancer Panel and Profiling Market, Patent Analysis (by Year), January 2020-October 2023
  • Figure 15: Genomic Cancer Panel and Profiling Market, Patent Analysis (by Country), January 2020-October 2023
  • Figure 16: Genomic Cancer Panel and Profiling Market Dynamics
  • Figure 17: Cancer Profiling Cases in Developed Countries
  • Figure 18: Share of Global Cancer Prevalence, 2010-2019
  • Figure 19: Share of Global Age-Standardized Death Rate of Cancer, 2010-2019
  • Figure 20: Genomic Research Funding by National Human Genome Research Institute (NHGRI), $Million, 2020, 2021, and 2022
  • Figure 21: Key Players Offering
  • Figure 22: Reimbursement Reductions Adopted for Oncology Testing as per PAMA Revisions
  • Figure 23: Cost Difference between the Multi-Gene Panel Test and Usual Care Screening Test
  • Figure 24: Share of Key Developments, January 2020-October 2023
  • Figure 25: Number of Product Launches, Approvals, and Upgradations (by Company), January 2020-October 2023
  • Figure 26: Growth-Share Analysis of the Genomic Cancer Panel and Profiling Market (by Technology), 2022
  • Figure 27: Genomic Cancer Panel and Profiling Market Snapshot (by Region), $Billion, 2022
  • Figure 28: Europe Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 29: Europe Genomic Cancer Panel and Profiling Market (by Application), $Million, 2022-2033
  • Figure 30: Europe Genomic Cancer Panel and Profiling Market (by End User), $Million, 2022-2033
  • Figure 31: Europe Genomic Cancer Panel and Profiling Market (by Country), $Billion, 2022-2033
  • Figure 32: Germany Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 33: France Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 34: U.K. Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 35: Italy Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 36: Spain Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 37: Rest-of-Europe Genomic Cancer Panel and Profiling Market, $Billion, 2022-2033
  • Figure 38: Genomic Cancer Panel and Profiling Market, Total Number of Companies Profiled
  • Figure 39: F. Hoffmann-La Roche Ltd: Product Portfolio
  • Figure 40: F. Hoffmann-La Roche Ltd: Overall Financials, $Million, 2020-2022
  • Figure 41: F. Hoffmann-La Roche Ltd: Revenue (by Segment), $Million, 2020-2022
  • Figure 42: F. Hoffmann-La Roche Ltd: R&D Expenditure, $Million, 2020-2022

List of Tables

  • Table 1: Genomic Cancer Panel and Profiling Market, Impact Analysis
  • Table 2: Technological Trends in the Genomic Cancer Panel and Profiling Market
  • Table 3: Genomic Cancer Panel and Profiling Market, Impact Analysis
  • Table 4: Genomic Cancer Panel and Profiling Market, Pipeline Tests
  • Table 5: Ongoing Cancer-Based Biomarkers Trials
  • Table 6: Europe Genomic Cancer Panel and Profiling Market, Impact Analysis